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Thyroid cancer is the most common endocrine malignancy and the incidence is rising.
Currently, there are no effective treatments for patients with advanced forms of thyroid
cancer. Anaplastic thyroid represents the most severe form of the disease with 95%
mortality at 6 months. It is therefore critical to better understand the mechanisms involved
in thyroid cancer development and progression in order to developmore effective therapeu-
tic strategies. Cell lines derived from thyroid tumors represent a critical tool to understand
the oncogenic mechanisms driving thyroid cancer, as well as preclinical tools to study the
efﬁcacy of new therapies in vitro and in vivo. For thyroid cancer, the development of new
therapies has been hampered by the lack of thyroid cancer cell lines in the widely used NCI-
60 panel which has been used to screen over 100,000 anti-cancer drugs. In addition, the
recent discovery that∼20 out of 40 existing thyroid cancer cell lines are either redundant or
misidentiﬁed with cell lines of other tissue lineages has further hampered progress in the
ﬁeld. Of the available cell lines, 23were identiﬁed as unique and presumably of thyroid origin
based on the expression of thyroid-speciﬁc genes.Thus, there is a great need for validated
thyroid cancer cell lines representing different stages of disease in addition to distinct onco-
genic mutations. New, authenticated thyroid cancer cell lines are beginning to be devel-
oped, adding to the tools available to study genes and pathways important for thyroid cancer
pathogenesis. In summary, the use of validated thyroid cancer cell lines that closely recapit-
ulate disease is critical for the discovery of new drug targets and ultimately new therapies.
Keywords: thyroid cancer cell lines, cell line misidentification, authenticated thyroid cancer cell lines, ATC,
PTC, FTC
INTRODUCTION
There are currently no effective therapies for patients with
advanced thyroid cancer, which includes patients diagnosed with
advanced papillary thyroid cancer (PTC) and anaplastic thyroid
cancer (ATC; Pﬁster and Fagin, 2008; Smallridge et al., 2009).
More than 1300 patients with thyroid cancer die each year from
this disease and the incidence is increasing (Leenhardt et al., 2004;
Davies and Welch, 2006; Xing, 2008; Enewold et al., 2009). ATC
is one of the most aggressive human cancers with greater than
95% mortality at 6 months. Extrathyroidal invasion and metasta-
sis are the most common causes of thyroid cancer-related death,
and althoughmuch effort has been devoted to decipher the mech-
anisms involved in the progression of this cancer, little progress
has been made in the development of new, effective therapies
at this stage (Pﬁster and Fagin, 2008; Smallridge et al., 2009).
Much attention has been devoted to the mitogen-activated pro-
tein kinase (MAPK) pathway as a therapeutic target due to the
large percentage of activating mutations in this pathway (BRAF,
RAS,RET/PTC; Gupta-Abramson et al., 2008), and although these
studies are promising, additional therapeutic strategies are needed
for the effective long-term treatment of advanced thyroid cancer
patients (Pﬁster and Fagin, 2008).
Cell lines represent a critical tool to study mechanisms driv-
ing cancer initiation and progression, and remain an essential
preclinical model to test new therapies. Although results using
cell lines do not always recapitulate the clinical response, cell
lines nonetheless remain an essential tool to test pro-tumorigenic
mechanisms and new therapies. Despite the importance of cell
lines, recent studies have shown that 18–36% of cell lines are
misidentiﬁed or cross-contaminated with other cell lines, thus
compromising the interpretations of numerous published studies
(Masters et al., 2001; Chatterjee, 2007; Lacroix, 2008; American
Type Culture Collection Standards Development Organization
WorkgroupASN-0002,2010). Cross-contaminationwith theHeLa
cell line is a well-known historical problem (MacLeod et al., 1999).
More recently, cross-contamination of newly developed cell lines
with older, established cell lines is becoming an increasingly rec-
ognized problem. Indeed, numerous misidentiﬁcations have been
reported, some within the well-studied NCI-60 panel of cell lines
(Lorenzi et al., 2009), in addition to cell lines thought to be of
prostate (van Bokhoven et al., 2001a,b, 2003), breast (Rae et al.,
2004, 2007; Liscovitch and Ravid, 2007), esophageal (Boonstra
et al., 2007), adenoid cystic carcinoma (ACC; Phuchareon et al.,
2009; Zhao et al., 2011), and head and neck squamous cell cancer
(HNSCC) origin (Zhao et al., 2011).
MISIDENTIFICATION OF THYROID CANCER CELL LINES
In 2008, we reported the comprehensive characterization of a
panel of 40 thyroid cancer cell lines (Schweppe et al., 2008). Using
genetic proﬁling, we showed that approximately 40% of these cell
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lines were either cross-contaminated with other thyroid cancer
cell lines, or misidentiﬁed with a cell lines from other tumor
types. Speciﬁcally, 6 out of 40 cell lines were redundant (iden-
tical to other thyroid cancer cell lines), and 10 were misidentiﬁed
with melanoma or colon cancer cell lines (Schweppe et al., 2008).
For these studies, we used short tandem repeat (STR) proﬁling,
which is the internationally approvedmethod for determining cell
line identity (Masters et al., 2001). Although STR proﬁling pro-
vides a powerful approach to determine genetic identity, it does
not provide information on tissue of origin. Thus, we analyzed
expression of the thyroid-speciﬁc transcription factors, Pax-8 and
TTF-1 to further characterize the origin of these cell lines. For the
misidentiﬁed cell lines of non-thyroid origin, expression of Pax-
8 and TTF-1 were low to undetectable by quantitative real-time
RT-PCR (qRT-PCR; unpublished observations). Of the remain-
ing 23 unique cell lines that are likely of thyroid origin, all
PTC and FTC cell lines expressed either Pax-8 and/or TTF-1,
and about half of the ATC cell lines expressed one or both of
these thyroid-speciﬁc transcription factors (Schweppe et al., 2008).
While expression of Pax-8 and/or TTF-1 do not prove or dis-
prove the origin of these cell lines, the presence of either Pax-8
or TTF-1 supports these cells being of thyroid origin. Critically,
none of the unique thyroid cancer cell lines available at the time
of this study have been genetically linked to their correspond-
ing tumors, due to the lack of original patient tissue samples.
Thus, it is difﬁcult to determine when thesemisidentiﬁcations and
cross-contaminations occurred. However, based on the timeline
of establishment, it is likely that these cell lines were established
by cross-contamination at the time of development (Schweppe
et al., 2008). To add to the number of misidentiﬁed thyroid can-
cer cell lines, the ONCO-DG-1 “thyroid cancer” cell line was
shown to be a misidentiﬁed with an ovarian cancer cell line, the
FB2 “thyroid cancer” cell line was shown to be a derivative of
the TPC1 cells, and the K1 cell line is likely a derivative of the
GLAG66 thyroid cancer cell line (Ribeiro et al., 2008; Schweppe
et al., 2008). Thus, it is clear that the development and charac-
terization of new, authenticated thyroid cancer cell lines that are
linked to their corresponding tissue samples is needed to com-
plement studies using the existing panel of genetically unique
cell lines to accurately study the mechanisms of thyroid can-
cer pathogenesis, and for the development of new therapeutic
strategies.
NEWMODELS TO STUDY THYROID CANCER BIOLOGY
The development of new cancer cell lines is a challenging task
with a low success rate, even for more aggressive tumors, and
the establishment of cell lines of thyroid origin appears to be a
particularly challenging task. Compared to other tumor types,
the number of thyroid cancer cell lines is relatively small. The
reasons for this low success rate are unclear, but could be partly
due to the overall less aggressive nature of these tumors. Of the
784 cancer cell lines in the SANGER database1, which maintains
data for cancer cell lines that are widely available to the scientiﬁc
community, only 5 of these are thyroid. Similarly, other major
databases, including GlaskoSmithKline (GSK), which contains
1http://www.sanger.ac.uk
genomic proﬁling data for>300 cancer cell lines2, and the Broad-
Novartis Cancer Cell Encyclopedia, which has data for 1000 cell
lines3, also only contain a handful of thyroid cancer cell lines.
While we identiﬁed 23 unique thyroid cancer cell lines, many of
these are not available in major repositories. The American Type
Culture Collection (ATCC) contains one thyroid cancer cell line
of medullary thyroid cancer (MTC) origin, while the German
Collection of Microorganisms and Cell Cultures (DSMZ) and
European Collection of Cell Cultures (ECACC) contain a handful
of genetically unique human thyroid cancer cell lines. Thus, the
development of new thyroid cancer cell lines genetically linked
to the original tissue sample is needed to improve our under-
standing of thyroid cancer biology, and once these cell lines are
developed, these cell lines should be made available to the scien-
tiﬁc community through a repository in order to maintain quality
control.
Recently, Marlow et al. (2010) reported the development and
characterization of four new ATC cell lines, THJ-11T, THJ-16T,
THJ-21T, andTHJ-29T.Of importance, STRproﬁling showed that
the newly developed cell lines are genetically unique and match
their corresponding tissue samples (Marlow et al., 2010). These
THJ cell lines represent the ﬁrst panel of thyroid cancer cell lines
that has beengenetically linked to their corresponding tissueof ori-
gin, providing a critical new tool to accurately study ATC biology.
Interesting, these cell lines exhibited similar patterns of chromo-
somal losses and gains compared to the original tumor tissue,
as determined by array-based comparative genomic hybridization
(CGH) analysis, suggesting thatminimal genetic drift has occurred
in culture (Marlow et al., 2010). The morphology of these cell
lines was shown to be squamoid, spindle, giant, or a combina-
tion of these morphologies, similar to the original tumor samples
(Marlow et al., 2010). Many of the common oncogenic alterations
in ATC were also identiﬁed in these cell lines, including mutations
in BRAF,TP53, RB, RAS, and PI3KCA (Marlow et al., 2010). Con-
sistent with the ATC origin of these cell lines, rearrangements in
RET/PTC and PAX-8/PPARγ were not identiﬁed. Oncogenic pro-
teins, including β-catenin, cyclin D1, survivin, and Bcl2 were also
evaluated and are expressed at varying levels in the different cell
lines, providing new tools to study common oncogenic signaling
pathways in thyroid cancer (Marlow et al., 2010). Thyroid-speciﬁc
gene expression was also evaluated by RT-PCR in this panel of
cell lines. Thyroglobulin (Tg), sodium iodide symporter (NIS),
and Pax-8 expression was detected in all four cell lines, TTF-1
expression was detected in three of these cell lines, while none of
these cell lines expressed thyroid peroxidase (TPO; Marlow et al.,
2010). Although TSH receptor (TSHR) expression was detected in
one cell line, TSHR was not correctly localized to the cell mem-
brane. All four cell lines were also shown to be tumorigenic in
nudemice (Marlow et al., 2010). Thus, the development and char-
acterization of these new ATC cell lines, which appear to closely
represent their tumor counterparts, will provide valuable models
to study the heterogeneity of ATC biology, and will be important
tools to test the efﬁcacy of new therapies using in vivo preclinical
models.
2http://array.nci.nih.gov
3http://www.broadinstitute.org/ccle/home
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Another set of new thyroid cancer cell lines was recently devel-
oped from follicular thyroid tumors derived from genetically
engineered mice expressing a loss-of-function Pten allele and an
oncogenic Kras, which results in constitutive activation of the
phosphatidylinostitol-OH kinase (PI3K) and MAPK pathways, a
common event in advanced thyroid cancers (Miller et al., 2009;
Dima et al., 2011). Unlike many immortalized cancer cell lines
established from advanced tumors, these three mouse cell lines
(T683, T691, and T826) were shown to have a relatively normal
karyotype, with normal chromosome numbers, and only rear-
rangements in chromosome 4 for two of the cell lines (Dima
et al., 2011). Common genetic alterations relevant to thyroid
cancer were also tested. Two of the cell lines exhibited com-
plete loss of the tumor suppressors, p16 and p19ARF, while p53
appeared to be functional (Dima et al., 2011). Consistent with a
poorly differentiated phenotype, expression of genes important
for thyroid differentiation and function, including Foxe1, Nkx2-
1, Pax-8, Duox1/2, Nis, Pds, TG, Tpo, and Tshr, were absent
(Dima et al., 2011). Due to constitutive activation of the PI3K and
MAPK pathways in these cell lines, inhibition of these pathways
with small molecule inhibitors was tested. As expected, inhi-
bition of either pathway alone resulted in partial inhibition of
growth, and dual inhibition of both the PI3K and MAPK path-
ways was more effective, similar to their results using primary cells
derived from these tumors (Miller et al., 2009; Dima et al., 2011).
Since PI3K can mediate activation of the glycolytic pathway in
tumors, lactate production and glycolytic metabolism was also
evaluated. Compared to normal thyrocytes, lactate production
was higher and cell growth was blocked by a glycolysis inhibitor,
suggesting that these FTC-derived cell lines have likely switched
to a glycolytic mode, and that inhibition of glycolysis may be a
potential new therapy for FTC (Dima et al., 2011). Finally, when
implanted into immunocompetent mice, all three cell lines were
shown to grow tumors and these mice developed lung metastases
(Dima et al., 2011). Thus, these new cell lines represent impor-
tant new tools to study the mechanisms of PI3K and MAPK
signaling, and provide a new model to study FTC tumor growth
and metastasis in an in vivo immunocompetent preclinical model
(Dima et al., 2011).
DEVELOPMENT OF NEW THERAPIES FOR THYROID CANCER
The recent discovery of misidentiﬁed thyroid cancer cell lines
has certainly hampered the progress in the ﬁeld (Ringel, 2008;
Schweppe et al., 2008). These misidentiﬁed cell lines have been
widely used in over 300 publications in the last 20 years, and as
recently reviewed by Kojic et al. (2011), these misidentiﬁed thy-
roid cancer cell lines, especially DRO90, ARO81, and NPA87, have
been used in a signiﬁcant number of preclinical studies to test
new targeted therapies for ATC. Thus, numerous studies using
these misidentiﬁed cell lines require reinterpretation and valida-
tion. The development of new therapies for thyroid cancer patients
has also been slowed by the lack of thyroid cancer cell lines in
the NCI-60 panel, which has been used to screen >100,000 anti-
cancer agents over the last ∼20 years, and has been widely used
to study global gene expression patterns and genomic alterations
(Shoemaker, 2006). Despite these problems, as outlined below,
progress has been made testing new therapies in validated thyroid
cancer cell lines, and overall thyroid cancer cell lines have made
major contributions to the understanding of thyroid cancer biol-
ogy and the identiﬁcation of new candidate targets for therapy
(Kojic et al., 2011).
Many of the oncogenic events contributing to thyroid cancer
pathogenesis have been identiﬁed. Genetic alterations in compo-
nents of the MAPK pathway, including BRAF,RAS, and RET/PTC
are common in PTC, while mutations in RAS and PPARγ/Pax-8
rearrangements are prevalent in FTC (Knauf and Fagin, 2009; Saji
and Ringel, 2010; Xing, 2010; Carlomagno and Santoro, 2011). For
ATC,mutations inBRAF andRAS are common, andmany of these
cancers harbor genetic alterations in PI3KCA andTP53 along with
activating mutations in the MAPK pathway (Knauf and Fagin,
2009; Saji and Ringel, 2010; Xing, 2010; Carlomagno and Santoro,
2011). Recently, a high proportion (∼80%) of metastatic thyroid
tumors was shown to exhibit dual activation of the MAPK and
PI3K pathways due to oncogenic mutations in BRAF and PIK3CA
or BRAF and AKT1 (Ricarte-Filho et al., 2009). Thus, the devel-
opment of new therapeutic strategies targeting these pathways is
of great interest.
Thyroid cancer cell lines provide an important source to better
understand oncogenic signaling mechanisms and to develop new
and improved therapies. Of importance, many of the oncogenic
alterations found in thyroid cancer, including mutations in BRAF,
RAS, PI3KCA, and RET/PTC1 are represented in currently avail-
able thyroid cancer cell lines (Schweppe et al., 2008). While early
studies used many of the misidentiﬁed cell lines to test agents
targeting the MAPK and PI3K signaling pathways, subsequent
studies using validated thyroid cancer cell lines have conﬁrmed
these results (Xing, 2009). Similar to studies in melanoma, thy-
roid cancer cell lines harboring a BRAF V600E mutation are in
general more sensitive to treatment with MKK1/2 and BRAF-
speciﬁc inhibitors (Solit et al., 2006; Leboeuf et al., 2008; Liu et al.,
2009, 2011a; Schweppe et al., 2009a; Salerno et al., 2010; Nucera
et al., 2011). Despite the presence of an activating BRAF muta-
tion, clinical studies are indicating that the response of thyroid
cancer patients to MAPK-directed therapies is not as promising as
melanoma patients. These results are consistent with preclinical
studies using cell lines, where Montero-Conde et al. (2011) have
shown BRAF-mutant thyroid cancer cell lines are less sensitive
to selective BRAF V600E inhibition compared to BRAF-mutant
melanoma cell lines. The reason(s) for this differing sensitivity are
unclear, but may be due to compensatory upregulation of other
pathways, including ErbB3 (Montero-Conde et al., 2011). Alter-
natively, EGFR signaling was recently shown to promote survival
in response to BRAF or MEK1/2 inhibition in BRAF-mutant thy-
roid and colon cancer cells, but not in melanoma (Prahallad et al.,
2012). Although further studies are needed in thyroid cancer, these
results suggest that combined inhibition of the MAPK pathway
and ErbB2 or EGFR may be beneﬁcial in BRAF-mutant thyroid
tumors.
Activation of the PI3K pathway represents anothermajor onco-
genic pathway in thyroid cancer. Recent studies targeting the PI3K
pathway have shown that thyroid cancer cells with activation of
the PI3K pathway are preferentially sensitive to inhibitors of this
pathway (Liu et al., 2009, 2011a). Despite these promising results,
it is not clear whether inhibition of the PI3K pathway alone will
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have sufﬁcient activity in advanced thyroid cancers as single agent
therapies. Indeed, recent studies have shown that dual targeting of
the MAPK and PI3K pathways may represent a more promising
strategy for thyroid tumors that harbor genetic alterations in both
pathways (Jin et al., 2009; Liu et al., 2010, 2011b). These studies
are consistent with the work from Dr. Di Cristafano’s laboratory
(discussed above) showing genetic activation of both the MAPK
and PI3K pathway is necessary for transformation of the thyroid
gland, and that dual inhibition of these pathways is more effective
than inhibition of either pathway alone (Miller et al., 2009; Dima
et al., 2011). Along with the discovery of co-existing mutations
of BRAF V600E with AKT1 or PIK3CA mutations in metastatic
thyroid lesions (Ricarte-Filho et al., 2009), these studies indicate
that dual targeting of the MAPK and PI3K pathways represent a
promising therapeutic strategy for patients with advanced thyroid
cancer.
Another promising therapeutic strategy for PTC and ATC is
targeting tyrosine kinase signaling with tyrosine kinase inhibitors
(TKIs). Of these, VEGF family members and its receptors have
been shown to play an important role in thyroid cancer, indepen-
dent of oncogenemutational status (Castellone et al., 2008; O’Neill
et al., 2010). Several studies have shown that VEGF and VEGFR2
are overexpressed in thyroid tumors, and that VEGF overexpres-
sion is associated with decreased disease-free survival and a poor
prognosis. Although initial reports used misidentiﬁed cell lines
to test the role of VEGFR in PTC and ATC (Kim et al., 2005),
recent preclinical studies have shown that treatment with vande-
tanib (ZD6474), a multi-kinase inhibitor of VEGFR, EGFR, and
RET, inhibits proliferation of ATC cells in vitro, likely via inhibi-
tion of the EGFR receptor, and blocks tumor growth in an in vivo
orthotopic ATC model, primarily through anti-angiogenic mech-
anismswhich are likelymediated byVEGFR2 (Gule et al., 2011). In
support of these preclinical studies, several phase II clinical trials
with anti-VEGFRmulti-kinase inhibitors are underway, including
vandetanib, sunitinib, axitinib, sorafenib, motesanib, and XL-184
with variable, but encouraging results (Castellone et al., 2008;
Perez et al., 2011).
The Src–focal adhesion kinase (FAK) tyrosine kinase pathway is
another emerging therapeutic target for thyroid cancer (Schweppe
et al., 2009b). Src and FAK are multifunctional non-receptor tyro-
sine kinases that are key regulators of growth, survival, migration,
and invasion (Kopetz et al., 2007; Schwock et al., 2010). In one
previous study, FAK protein was shown to be overexpressed in
a subset of PTC and ATC, but the phosphorylation status of
FAK was not examined (Kim et al., 2004). We were the ﬁrst to
show that FAK is phosphorylated in a subset of PTC patient
tumor samples (Schweppe et al., 2009b). We further showed
that FAK is phosphorylated in a panel of validated thyroid can-
cer cells, and that the growth and invasion of cells with high
phospho-FAK are sensitive to treatment with the Src inhibitor,
saracatinib (AZD0530; Schweppe et al., 2009b). Inhibition of
growth and invasion was independent of oncogenic mutations
in the MAPK pathway, suggesting that the FAK-Src pathway
represents another major pro-tumorigenic signaling pathway in
thyroid cancer, independent of MAPK signaling. Clinical trials are
underway testing Src inhibitors in solid tumors, including BMS-
354,825 (dasatinib; Bristol-Myers Squibb), bosutinib (SKI-606,
Wyeth; Quintas-Cardama et al., 2007), and the more selective Src
inhibitor, AZD0530 (saracatinib; AstraZeneca; Hennequin et al.,
2006; Santini et al., 2010). Recently, FAK inhibitors have been
developed, and two ATP-dependent small molecule inhibitors,
including NVP-TAE-226 and the more selective PF-562,271, have
entered clinical trials (Halder et al., 2007; Roberts et al., 2008;
Siu et al., 2008; Schwock et al., 2010). Thus, future studies test-
ing the efﬁcacy of Src and FAK inhibitors in advanced thyroid
cancer will be of great interest.
CONCLUDING REMARKS
Progress is being made in the development and characteriza-
tion of new thyroid cancer cell lines. The majority of currently
available cell lines represent PTC and ATC, while FTC-derived
cell lines remain underrepresented. Importantly, while the major
oncogenic mutations found in thyroid tumors are represented in
many of the available cell lines (BRAF, RAS, PI3KCA, RET/PTC1),
some of the less common genetic alterations, including AKT1,
which is likely important in metastatic thyroid cancer (Ricarte-
Filho et al., 2009), speciﬁc RET/PTC isoforms, which play distinct
roles in PTC pathogenesis, and PPARγ/Pax-8 rearrangements,
which are important in FTC, are not represented in the current
panel of cell lines (Schweppe et al., 2008). For further trans-
lational relevance, studies with permanent cell lines should be
complementedwith studies usinghuman tissue samples, andwhen
possible, primary culture models, which may better recapitulate
the original tumor. In conclusion, the continued development
and characterization of new cell line models that are geneti-
cally linked to the original patient tissue samples is critical to
further understand the oncogenic properties of thyroid can-
cer cells, identify novel targets for therapy, and to translate
these ﬁndings to the clinic for patients with advanced thyroid
cancer.
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